MANKIND PHARMA LIMITED vs MAX HEALTHCARE INS LTD

A side-by-side comparison of MANKIND PHARMA LIMITED (MANKIND) and MAX HEALTHCARE INS LTD (MAXHEALTH) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, MAX HEALTHCARE INS LTD leads MANKIND vs MAXHEALTH on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability04
  • Growth11
  • Size & financial health22
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

MANKIND takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

51.25
P/E ratio
67.23
6.30
P/B ratio
12.29
0.04%
Dividend yield
0.20%
₹46.34
EPS
₹14.82

Profitability

MAXHEALTH takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

13.10%
Return on equity
14.80%
14.00%
Return on capital
15.00%
25.00%
EBITDA margin
27.00%
13.57%
Net margin
17.22%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

17.73%
Revenue CAGR (3Y)
22.43%
13.94%
Profit CAGR (3Y)
9.31%

Size & financial health

Even

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹97,296 Cr
Market cap
₹97,711 Cr
₹14,278 Cr
Revenue
₹8,373 Cr
₹1,938 Cr
Net profit
₹1,442 Cr
0.34
Debt / equity
0.09
MANKIND PHARMA LIMITED
  • + ["Company has reduced debt."]
  • ["Promoter holding has decreased over last 3 years: -3.87%"]
MAX HEALTHCARE INS LTD
  • ["Stock is trading at 9.18 times its book value", "Tax rate seems low", "Company has a low return on equity of 13.7% over last 3 years.", "Company might be capitalizing the interest cost", "Dividend payout has been low at 13.6% of profits over last 3 years"]
MANKIND PHARMA LIMITED full analysis MAX HEALTHCARE INS LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.